Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Lycojaponicumin A in drug for treating yellow fever virus infection

A yellow fever virus and drug technology, applied in the field of biomedicine, to achieve the effect of huge social benefits and research value

Active Publication Date: 2013-12-18
CANVEST WUHAN BIOTECH
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there have been no cases reported in China, but this does not make us relax our vigilance against the virus, because China's climate and geographical environment are complex, and there are many types of mosquitoes, which have the conditions for transmission. At the same time, with the increasing frequency of international exchanges, YFV It is very likely that it will be introduced into China

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Lycojaponicumin A in drug for treating yellow fever virus infection
  • Application of Lycojaponicumin A in drug for treating yellow fever virus infection
  • Application of Lycojaponicumin A in drug for treating yellow fever virus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Embodiment 1: the preparation of the compound Lycojaponicumin A tablet involved in the present invention:

[0039] Take 20 grams of compound Lycojaponicumin A, add 180 grams of conventional excipients for tablet preparation, mix well, and make 1000 tablets with a conventional tablet press.

Embodiment 2

[0040] Embodiment 2: the preparation of the compound Lycojaponicumin A capsules involved in the present invention:

[0041] Get 20 grams of compound Lycojaponicumin A, add conventional auxiliary materials such as starch 180 grams for the preparation of capsules, mix well, and pack into capsules to make 1000 tablets.

[0042] The following pharmacodynamic experiments will further illustrate its drug activity.

experiment example 1

[0044] A kind of application of Lycojaponicumin A in the preparation treatment or prevention yellow fever virus infection medicine, its steps are:

[0045] Toxicity of A. Lycojaponicumin A to Vero cells

[0046] Vero cells (African green monkey kidney cells) are susceptible cells to YFV.

[0047] The experimental steps are as follows:

[0048] 1: Inoculate Vero cells: Use DMEM medium containing 10% (v / v) fetal bovine serum to make a single cell suspension, inoculate 1000-10000 cells per well into a 96-well cell culture plate, and inoculate a volume of 100ul per well ;

[0049] 2: Culture Vero cells: at 37°C, 5% (v / v) CO 2 Under culture conditions, cultivate for 2 days;

[0050] 3: Add Lycojaponicumin A: Discard the DMEM medium in each well, add 100ul to each well and dilute to the corresponding concentration with DMEM medium containing 10% (v / v) fetal bovine serum (0uM, 0.4uM, 1.2 uM, 3.7uM, 11uM, 33uM, 100uM, 300uM) Lycojaponicumin A, add 100ul of DMEM medium without 10%...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of Lycojaponicumin A in preparation of a drug for treating or preventing yellow fever virus infection. The Lycojaponicumin A can effectively inhabit yellow fever virus proliferation, but has low cytotoxicity, can be further developed for the preparation of drugs for treating diseases caused by yellow fever virus infection and has wide application prospect. The application of the Lycojaponicumin A in the preparation of the drug for treating the yellow fever virus infection is disclosed for the first time. Due to the fact that the skeleton type is a novel skeleton type and the high yellow fever virus inhibiting activity of the Lycojaponicumin A is unexpectedly strong, the possibility that other compounds give any revelation does not exist, and the Lycojaponicumin A has outstanding substantive characteristics and meanwhile has a remarkable improvement in prevention and treatment of the yellow fever virus infection obviously.

Description

technical field [0001] The invention belongs to the field of biomedicine, and more specifically relates to the application of Lycojaponicumin A in the preparation of medicines for treating or preventing yellow fever virus infection. Background technique [0002] Yellow fever virus (YFV) is a member of the Flavivirus genus in the family Flaviviridae. Yellow fever virus causes yellow fever, an acute infectious disease. Yellow fever has been designated as a quarantine infectious disease internationally, and China has also designated it as a Class A infectious disease. In 1648, the YUCATAN peninsula in America first confirmed the prevalence of yellow fever. From the 17th to the 19th century, the disease was brought to Europe and North America through transportation. Within two centuries, yellow fever became one of the most serious plagues in some parts of the United States, Africa, and Europe, causing a large number of deaths. Since the 20th century, the disease has not occur...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/424A61P31/14
CPCY02A50/30
Inventor 江春平王慧
Owner CANVEST WUHAN BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com